Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10.
about
Differential involvement of trigeminal transition zone and laminated subnucleus caudalis in orofacial deep and cutaneous hyperalgesia: the effects of interleukin-10 and glial inhibitorsThe "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting gliaEvidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1betaIntrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in ratsNeuroimmune mechanisms of stress: sex differences, developmental plasticity, and implications for pharmacotherapy of stress-related diseaseOsteoarthritis joint pain: the cytokine connectionSpinal interleukin-10 therapy to treat peripheral neuropathic painIL-10 mediated by herpes simplex virus vector reduces neuropathic pain induced by HIV gp120 combined with ddC in ratsPEGylation of interleukin-10 for the mitigation of enhanced pain states.Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain.Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord.Bilateral changes of TNF-alpha and IL-10 protein in the lumbar and cervical dorsal root ganglia following a unilateral chronic constriction injury of the sciatic nerveMonocytes/Macrophages control resolution of transient inflammatory pain.Efficacy of some non-conventional herbal medications (sulforaphane, tanshinone IIA, and tetramethylpyrazine) in inducing neuroprotection in comparison with interleukin-10 after spinal cord injury: A meta-analysis.Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes.Spinal actions of lipoxin A4 and 17(R)-resolvin D1 attenuate inflammation-induced mechanical hypersensitivity and spinal TNF release.Systemic inflammation decreases pain threshold in humans in vivo.Prior exposure to glucocorticoids potentiates lipopolysaccharide induced mechanical allodynia and spinal neuroinflammationDevelopment of viral vectors for gene therapy for chronic painCurrent gene therapy using viral vectors for chronic painDivergent cerebrospinal fluid cytokine network induced by non-viral and different viral infections on the central nervous system.Design of a covalently linked human interleukin-10 fusion protein and its secretory expression in Escherichia coli.Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing.Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells.Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain.Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administrationViral vector-based gene transfer for treatment of chronic pain.Gene therapy applications for the treatment of neuropathic pain.From neuroanatomy to gene therapy: searching for new ways to manipulate the supraspinal endogenous pain modulatory system.HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microgliaAnticytokine therapy in neuropathic pain management.IL4-10 Fusion Protein Is a Novel Drug to Treat Persistent Inflammatory Pain.Applications of gene therapy to the treatment of chronic pain.Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNF alpha.Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses.Glia in pathological pain: a role for fractalkineRecombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery.Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain.CD8+ T Cells and Endogenous IL-10 Are Required for Resolution of Chemotherapy-Induced Neuropathic Pain.Long-term control of neuropathic pain in a non-viral gene therapy paradigm.
P2860
Q21203940-C7A95F72-CAEC-4B84-89D8-B37D2D9D69C6Q24650739-047A1B90-5B47-4ED5-8198-A21B55499FCDQ24656645-46BA4960-444B-4C17-87BC-85262250CB61Q25256466-B513CAE8-25A2-4958-A9B0-2531C1AA92FBQ26801437-E3321CE6-EBDF-4CE3-8B53-675610060428Q26859004-8A035382-AB8D-4E75-A49D-AF4DA79F6048Q26861391-E6B3A09F-1563-4578-B49F-DC982EF90387Q28577054-59527404-B9D2-4EFA-B645-107D013A08D7Q33505369-8DF18CBF-8B0A-4242-82A7-F81C0AB33BEFQ33562058-F0C44CA5-AB8A-4DDD-A9A3-BA5A127CD3D4Q33581344-DE94C407-0552-45C6-919E-18179AA475C2Q33687631-4CAA5DA4-9990-482A-B630-9696EF767983Q33823432-B19DB88F-96A9-48CA-9C83-6A5E379DFD41Q34041359-0E4A87B0-87C7-4980-8035-B9D91609F9FDQ34642112-F8604024-4E53-4F92-840C-48BC92F51CA5Q35005722-D6CBFDD8-AB7C-4395-82F7-504DF0DB9AA9Q35073261-BD58512E-3C7A-4B37-A31B-8F262D9FDA46Q35194571-5700B2BD-2682-49D4-8373-E6F5D27A66A1Q35430864-8B59EA53-5267-43BA-976F-73E3E11891D5Q35658521-CAE0FFCA-A0F5-4DDC-94D8-B8B05EE6518EQ35749605-DF3F7CF4-0E5D-4BFD-A50F-1F0CAF7B5DAEQ36080839-FC7ACB57-C56D-4903-8858-D02806B9D086Q36229734-A8C577C9-EA39-487A-BA98-423E4843694CQ36274402-D18917BE-E413-4D67-B4CF-B7F9D2269C9CQ36458975-87B36E6F-B52E-4D76-B774-521A14F6DB60Q36642679-EE6AC1DF-91B5-4866-910C-D33B92093698Q36787828-27DEFEE2-C0E9-46AE-8BDD-DD4C7FB2BFE2Q36817045-E8E0AA7F-FF79-483D-9EA0-475C0D4A97A9Q36861028-B907683E-2293-4BAE-9341-8E17B9E0B8C5Q36948465-53725AB9-D662-4410-BBEB-189706DE952DQ36998861-829EED10-A7CC-457C-AA08-BAEAF78500A5Q37096038-E7654368-6654-47D1-8940-44E63664903EQ37108334-00D02CCB-1F9A-4A1F-8F94-D5F4D8507DA7Q37134881-DCF09C86-7641-4C25-A191-35CFA1AD7D7FQ37175799-3A23A2F4-D65B-46B1-83FE-E387B4A0F9A6Q37189198-1B9A47AE-C9FD-4439-85D5-4814868AA605Q37355740-44E8FC79-CD40-4A81-8DFE-F94C02964B33Q37388717-833562CD-2ADA-4393-BE94-AAC1556214B9Q37398478-A460A221-799D-4C49-9C67-577752B98924Q37406988-4D6553C3-F15D-446A-9837-B95BCEE09334
P2860
Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Controlling pathological pain ...... tory cytokine, interleukin-10.
@en
Controlling pathological pain ...... tory cytokine, interleukin-10.
@nl
type
label
Controlling pathological pain ...... tory cytokine, interleukin-10.
@en
Controlling pathological pain ...... tory cytokine, interleukin-10.
@nl
prefLabel
Controlling pathological pain ...... tory cytokine, interleukin-10.
@en
Controlling pathological pain ...... tory cytokine, interleukin-10.
@nl
P2093
P2860
P1476
Controlling pathological pain ...... tory cytokine, interleukin-10.
@en
P2093
David Martin
Erin D Milligan
Evan M Sloane
John R Forsayeth
Kevin O'Connor
Kirk Johnson
Leslie A Leinwand
Raymond A Chavez
Stephen J Langer
P2860
P304
P356
10.1111/J.1460-9568.2005.04057.X
P407
P577
2005-04-01T00:00:00Z